Current pharmaceutical biotechnology最新文献

{"title":"Wound Dressing Potential of Bacterial Cellulose Produced by Acetobacter tropicalis NBRC 16470 Strain Isolated from Rotten Fruits.","authors":"Halil Bal","doi":"10.2174/0113892010361594250703060501","DOIUrl":"https://doi.org/10.2174/0113892010361594250703060501","url":null,"abstract":"<p><strong>Background: </strong>Bacterial cellulose, which is used in many fields from biomedicine to electronics, is promising as an alternative wound dressing instead of traditional gauze in wound treatment.</p><p><strong>Objectives: </strong>The objective of this study was to evaluate the potential use of cellulose produced by acetic acid bacteria isolated from rotten fruits as a wound dressing.</p><p><strong>Methods: </strong>In our study, rotten fruit samples were incubated in Hestrin-Schramm (HS) Broth medium. Then, a loopful of the pellicle-forming samples was taken and inoculated onto Hestrin- Schramm (HS) agar using the streak culture method and bacteria were isolated. Identification of bacteria was performed using the BLAST program after 16S rRNA sequence analysis. Physicochemical properties and morphological characterization of bacterial cellulose produced by static culture were examined using Fourier transform infrared (FTIR) and scanning electron microscopy (SEM), respectively, and the swelling ratio was investigated. Antibiotic susceptibilities of bacterial cellulose membranes impregnated with different concentrations of gentamicin (50 μg/mL, 100 μg/mL, 200 μg/mL) against Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 25922 were determined by the disk diffusion method.</p><p><strong>Results: </strong>The bacteria isolated from rotten fruits were identified as Acetobacter tropicalis NBRC 16470. The structure of cellulose produced by static culture was confirmed by a peak at 3,240 cm-1 in FTIR analysis and fibril structures in SEM analysis. Bacterial cellulose had a swelling ratio of 27.37± 2 .99 fold. The zone diameters formed by bacterial cellulose disk (50 μg/mL gentamicin) and gentamicin (10 μg) disk against Staphylococcus aureus ATCC 29213 and Escherichia coli ATCC 25922 were almost the same.</p><p><strong>Conclusion: </strong>The production of bacterial cellulose, which has the potential to be used as a wound dressing from rotten fruits, is important in terms of recycling and low cost.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Flavonoids as Antimicrobial Agents: A Comprehensive Review of Mechanisms and Therapeutic Potential.","authors":"Vishal Sharma, Diksha Sharma, Mamta Saini, Akash Jain, Jasmine Chaudhary, Navgeet Kaur, Samir Sahoo, Sachin Kumar Singh, Kavita Goyal, A Rekha, Haider Ali, Saurabh Gupta, Md Sadique Hussain, Gaurav Gupta","doi":"10.2174/0113892010384002250628163849","DOIUrl":"https://doi.org/10.2174/0113892010384002250628163849","url":null,"abstract":"<p><p>Flavonoids, plant-derived polyphenolic compounds, have garnered significant attention for their broad-spectrum antimicrobial potential, encompassing antibacterial, antifungal, and antiviral activities. These bioactive molecules exert their effects through multiple mechanisms, including disruption of microbial cell membranes, inhibition of nucleic acid synthesis, suppression of biofilm formation, and interference with key bacterial enzymes. Notable flavonoids such as quercetin, apigenin, and kaempferol exhibit potent activity against bacterial pathogens like Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa, as well as fungal pathogens such as Aspergillus fumigatus and Candida albicans. Furthermore, flavonoids can potentiate the efficacy of conventional antibiotics by inhibiting bacterial efflux pumps, a critical mechanism contributing to antibiotic resistance. Recent advancements in structure-activity relationship (SAR) studies have underscored the influence of structural modifications- such as prenylation, hydroxylation, and methoxylation-on the antimicrobial potency of flavonoids. By highlighting these insights, this review provides a unique perspective on flavonoid-based antimicrobial strategies, particularly their synergistic potential with existing antibiotics. These findings position flavonoids as promising candidates for novel antimicrobial therapies, particularly in the face of increasing antibiotic-resistant pathogens. However, further research is needed to elucidate their precise mechanisms and optimize their therapeutic applications.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Green Synthesis of Silver Nanoparticles Using Grewia tiliaefolia Vahl Leaf Extract: Characterisation, Process Optimisation and Hepatoprotective Activity Against Paracetamol-Induced Liver Toxicity in Rats.","authors":"Dharmasoth Rama Devi, Mebrahtu Hagos Kahsay, Ganga Rao Battu, Keloth Basavaiah, Vinay Bharadwaj Tatipamula","doi":"10.2174/0113892010385169250616044545","DOIUrl":"https://doi.org/10.2174/0113892010385169250616044545","url":null,"abstract":"<p><strong>Introduction: </strong>Scientists around the world are focusing on 'green,' environmentfriendly, and cost-effective green synthesis of nanometals using various plant extracts to combat various ailments. Among nanometals, Silver (Ag) is one of the most commercialised nanomaterials due to its wide applications in biotechnology and biomedical fields. The present study reports the first facile synthesis, characterization, and process optimisation of Ag nanoparticles (NPs) using aqueous Grewia tiliaefolia leaf extract (Gt) as a reducing and surface functionalising agent.</p><p><strong>Methods: </strong>Characterisation of Gt-mediated Ag-NPs was performed using FTIR. The morphology and microstructures of Gt-derived Ag-NPs were analysed using TEM and FE-SEM. In vitro, antioxidant activity was evaluated against DPPH radicals, hydrogen peroxide radicals, and ferric ions. In vitro, anticancer activity was assessed on MCF-7 and HepG2 cell lines. In vivo, hepatoprotective activity was tested against paracetamol-induced liver toxicity in rats.</p><p><strong>Results: </strong>FTIR analysis confirmed the interaction between Ag-NPs and Gt. The optimal conditions for Gt-derived Ag-NPs were found to be 4 mM AgNO3, 5% Gt, at 90°C for 60 minutes, at pH 9. UV-Visible spectroscopy, XRD, FE-SEM, and TEM revealed the phase formation, spherical morphology, and surface functionalisation of Gt-derived Ag-NPs, which were stable (-28.3 mV) with an average particle size of 14.5±0.05 nm. The Gt-derived Ag-NPs were found to be highly effective in significantly inhibiting DPPH radical, ferric ions, and hydroxyl radicals. Additionally, the cytotoxicity of Gt-derived Ag-NPs was more effective against MCF-7 cells compared to HepG2 cells. They also exhibited dose-dependent protection against hepatoprotective activity in albino rats.</p><p><strong>Discussion: </strong>The hepatoprotective effects of Gt-mediated Ag-NPs likely result from the combined action of bioactive phytochemicals (such as α/β-amyrin, γ-lactones, betulin, and lupeol), and their ability to scavenge ROS, reduce oxidative stress, and modulate inflammatory pathways. These mechanisms, supported by reduced lipid peroxidation and increased antioxidant activity in paracetamol-induced hepatotoxicity, suggest their therapeutic potential in liver protection and regeneration.</p><p><strong>Conclusion: </strong>Overall, Gt proves to be an eco-friendly and non-toxic source for synthesizing bioactive Ag-NPs at optimal conditions.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elucidating the Role of Gardeniae Fructus and Scutellariae Radix Herb Pair in Alzheimer's Disease via Network Pharmacology: Emphasis on Oxidative Stress, and the PI3K/Akt Pathway.","authors":"Jia Xi Ye, Jia Ying Wu, Min Zhu, Liang Ai, Qihui Huang","doi":"10.2174/0113892010326797250422095516","DOIUrl":"https://doi.org/10.2174/0113892010326797250422095516","url":null,"abstract":"<p><strong>Background: </strong>The combination of Gardeniae Fructus (ZZ) and Scutellariae Radix (HQ) is a traditional Chinese medicine used for Alzheimer's disease (AD). However, the molecular mechanisms underlying its anti-dementia effects, particularly its multi-component synergy and pathway modulation, remain poorly understood.</p><p><strong>Objective: </strong>Our study employed an integrated systems pharmacology approach to mechanistically decode the anti-AD properties of ZZ-HQ, combining network pharmacology predictions, molecular docking simulations, and experimental validation to identify critical bioactive components, molecular targets, and therapeutic pathways.</p><p><strong>Methods: </strong>A comprehensive network pharmacology analysis was performed to identify bioactive compounds within the ZZ-HQ complex and their potential protein targets associated with AD. Molecular docking was utilized to predict and assess the binding interactions between key bioactive compounds and AD-related protein targets. Experimental validation focused on baicalin, a major active compound in the ZZ-HQ complex, evaluating its effects on cell viability, apoptosis regulation, oxidative stress reduction, and the activation of the PI3K/Akt signaling pathway.</p><p><strong>Results: </strong>Fifty-four bioactive compounds were identified in the ZZ-HQ complex, interacting with 258 AD-associated proteins. Key compounds, such as baicalein and norwogonin, demonstrated strong binding affinities with pivotal proteins, including SRC and PIK3R1. Experimental studies further confirmed that baicalin significantly improved cell viability by activating the PI3K/Akt pathway, reducing apoptosis, and alleviating oxidative stress.</p><p><strong>Conclusion: </strong>Our study uncovered the therapeutic potential of the ZZ-HQ combination in addressing AD through multi-target mechanisms, particularly via modulation of the PI3K/Akt pathway and oxidative stress. These findings provide a scientific basis for the pharmacological effects of ZZ-HQ and offer valuable insights for further research on its potential application in AD treatment.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HIV Co-infected with Asymptomatic Visceral Leishmaniasis Exhibited a High Prevalence of the B type HBV Genotype.","authors":"Shiril Kumar, Ganesh Chandra Sahoo, Krishna Pandey, Ashish Kumar","doi":"10.2174/0113892010310175250618134149","DOIUrl":"https://doi.org/10.2174/0113892010310175250618134149","url":null,"abstract":"<p><strong>Background: </strong>Multiple organisms infect the host simultaneously in the case of coinfection. This study intended to determine the prevalence of viral hepatitis B in HIV/Asymptomatic VL co-infected patients and to identify the HBV genotype circulating in these patients in Bihar, India.</p><p><strong>Methods: </strong>There were 96 archived samples with co-infection with HIV and asymptomatic VLpositivity included in this study. A real-time PCR test was performed to measure the load of HBV DNA, and a chemiluminescent immunoassay was performed to determine the level of HBsAg.</p><p><strong>Results: </strong>Our study evaluated HIV and AVL co-infected patients with two coexisting genotypes of HBV and observed the expression of the B, C, and D genotypes. HBsAg levels correlated directly with HBV DNA levels in almost every case.</p><p><strong>Conclusion: </strong>For a better understanding of this disease, authors need approaches and strategies for improving the current diagnostic techniques, as well as studies focusing on vector control procedures and other operational tools.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges and Progress of Orphan Drug Development for Rare Diseases.","authors":"Abhijit Debnath, Rupa Mazumder, Avijit Mazumder, Pankaj Kumar Tyagi, Rajesh Kumar Singh","doi":"10.2174/0113892010371761250616112614","DOIUrl":"https://doi.org/10.2174/0113892010371761250616112614","url":null,"abstract":"<p><p>Rare diseases, defined as conditions affecting fewer than 200,000 people in the United States or less than 1 in 2,000 people in Europe, pose significant challenges for healthcare systems and pharmaceutical research. This comprehensive review examines the evolving landscape of orphan drug development, analyzing scientific, economic, and regulatory challenges while highlighting recent technological breakthroughs and innovative approaches. We explore how artificial intelligence, next-generation sequencing, and personalized medicine are revolutionizing rare disease research and treatment development. The review details key advances in therapeutic approaches, including gene therapy, cell-based treatments, and drug repurposing strategies, which have led to breakthrough treatments for previously untreatable conditions. We analyze the impact of international collaborations, such as the International Rare Diseases Research Consortium, and discuss how regulatory frameworks worldwide have evolved to accelerate orphan drug development. The paper highlights the growing market for orphan drugs, projected to reach $242 billion by 2024 while examining the complex challenges of ensuring treatment accessibility and economic sustainability. We assess innovative clinical trial designs, patient registry development, and emerging strategies in personalized medicine that are transforming the field. Despite notable advancements, significant gaps remain in diagnosis, treatment accessibility, and sustainable funding for rare disease research. The review concludes by proposing specific actions for enhancing international collaboration, improving patient registries, and aligning incentives to address the unmet medical needs of rare disease patients, emphasizing the critical role of continued public-private partnerships and technological innovation in advancing orphan drug development.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards a Personalized Medicine Approach for HCC.","authors":"Radhika Tippani, Pallavi Kagithoju, Ranjith Pabbati, Maheswara Reddy Mallu, Mahendar Porika","doi":"10.2174/0113892010366459250616125419","DOIUrl":"https://doi.org/10.2174/0113892010366459250616125419","url":null,"abstract":"<p><p>Owing to the lack of appropriate selective treatments, hepatocellular carcinoma (HCC) remains one of the major reasons of cancer associated death. Chronic liver failure nearly always accompanies HCC, and doctors usually detect it only after the disease has progressed beyond the point where curative therapies are possible. Despite the fact that HCC has distinct morphological and phenotypic patterns, therapeutic options are limited to comparatively homogeneous drugs such as multi-targeted tyrosine kinase blockers and immune checkpoint blockers. Multiple studies evaluating the effectiveness of different medications have yielded disappointing findings, indicating that HCC has poor immunity to chemotherapy, which is exacerbated by multidrug resistance. As a result, more successful therapies addressing HCC's disordered metabolic and molecular pathways are needed. The quite often change in sequence of genes and molecular targets in HCC patients are telomerase reverse transcriptase, Wnt/-catenin signaling pathway oncogene (CTNNB1), and the TP53 gene, according to integrated genomic profiling. Furthermore, new approaches like genome-scale metabolic replicas may be utilized to explicate the basic cancer specific metabolism, allowing for such exploration of promising biomarkers and drug candidates. The clinical implications of metabolic network driven heterogeneity of HCCcaseson the basis of redox response, metabolite use, and subtype specific pathways could help accelerate the advancement of personalised medicine. Another interesting strategy is microRNA- based therapy which involves miRNA antagonists to block oncogenic miRNAs and miRNA substitution, which entails reintroducing a tumor-suppressor miRNA to restore function following a functional impairment. The existing and evolving clinical purpose in context of molecular targets and metabolic network-based approaches are summarised in this review, paving the way for successful HCC patient care.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multidisciplinary Approach for Developing a Natural Antifungal Formulation Targeting Oropharyngeal Candidiasis: A Mini-review.","authors":"Alaa T Rajkhan, Odai I Medhesh, Duaa Bafail, Osama Abdelhakim Ahmed, Abdelbagi Alfadil Musa, Ahmed Shaker Ali, Ibrahim M Ibrahim","doi":"10.2174/0113892010374288250612065712","DOIUrl":"https://doi.org/10.2174/0113892010374288250612065712","url":null,"abstract":"<p><strong>Background: </strong>Oropharyngeal candidiasis (OPC), a fungal infection affecting the mouth and throat, imposes a substantial burden on vulnerable populations such as HIV/AIDS patients, cancer treatment recipients, and the elderly. Conventional antifungal medications are encountering increasing resistance and side effects, necessitating the exploration of novel therapeutic approaches.</p><p><strong>Objectives: </strong>This review proposes a comprehensive strategy for developing a novel natural product- based antifungal formulation targeting OPC. The approach involves harnessing promising natural compounds with established antifungal properties and employing advanced delivery systems like mucoadhesive microemulsions to improve efficacy and minimize adverse effects. Additionally, the review explores the integration of computational methods to expedite the identification and development of potent antifungal agents.</p><p><strong>Methods: </strong>A comprehensive literature review was conducted using databases such as PubMed, Scopus, and Web of Science. Search terms included combinations of \"oropharyngeal candidiasis,\" \"natural antifungal agents,\" \"flavonoids,\" \"mucoadhesive microemulsions,\" \"computational drug discovery,\" and \"in vitro/in vivo studies.\" Priority was given to studies published within the last ten years.</p><p><strong>Results: </strong>The review identifies promising natural compounds with antifungal activity against Candida species commonly associated with OPC. Additionally, several studies highlight the potential of computational tools such as molecular docking and in silico ADMET for rapidly identifying natural compounds with potent antifungal activity and favorable pharmacokinetic and safety profiles. A brief overview of in vitro and in vivo experiments is provided, emphasizing their role in validating the safety and efficacy of the proposed natural product-based antifungal formulation. Formulation and analytical aspects are also discussed.</p><p><strong>Conclusion: </strong>The multidisciplinary approach outlined, incorporating natural products, computational methods, advanced preclinical in vitro and in vivo experiments, and advanced delivery systems, offers promise for the rapid, cost-effective development of safe and effective optimized formulations to address the growing challenge of OPC, particularly in vulnerable populations.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and Preliminary In vitro Investigation on Core Shell Nanoparticles Laden In Situ Gel for Corneal Neovascularization.","authors":"Harita Desai, Pranav Shah, Vikas Sawant, Rashmi Singh","doi":"10.2174/0113892010336099241220165806","DOIUrl":"https://doi.org/10.2174/0113892010336099241220165806","url":null,"abstract":"<p><strong>Background: </strong>The inherent limitation of ocular dosage forms is decreased precorneal residence time which affects the bioavailability and therapeutic efficacy.</p><p><strong>Objective: </strong>The objective of the current research was to sustain drug release and enhance precorneal drug residence time by formulating lipidic core-shell nanoparticles of Dexamethasone Sodium Phosphate and loading them in ion-sensitive in situ gel for corneal neovascularization.</p><p><strong>Methods: </strong>Polymeric nanoparticles were formulated using Eudragit L100-55 and PVA by twostep solvent diffusión nanoprecipitation method and coated by a lipidic film of Soya phosphatidylcholine with Cholesterol. The optimized lipidic core-shell nanoparticles were transformed into in situ gel using Gellan gum. The lipidic core-shell nanoparticles were evaluated for particle size, zeta potential, entrapment efficiency, in vitro reléase and in situ gel was evaluated for in vitro gelling time, pH, drug content, HETCAM studies, etc Results: The Core-shell lipid nanoparticles exhibited a particle size of 368.00±0.54 nm and zeta potential -13.3±2.0 mV respectively. The lipidic core-shell nanoparticles were found to show a sustained drug release when compared to the drug solution. The optimized in situ gel was found to show a gelation time of 39.59±2.49 seconds and was found to be non-irritant.</p><p><strong>Conclusion: </strong>A decline in ex vivo drug permeation was observed through an aqueous suspension of core-shell polymeric nanoparticles and core-shell LPN loaded in situ gel thus confirming sustained release for the drug Dexamethasone Sodium Phosphate.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Weight Loss Mechanism of Hydroxysafflor Yellow A in Obese Mice: Involvement of Immune Inflammation via Prkcd, Btk, and Vav1 Genes in Adipose Tissue.","authors":"Ruizhen Hou, Wenjing Hu, Kemin Yan, Xiaorui Lyu, Yuchen Jiang, Xiaonan Guo, Yuxing Zhao, Linjie Wang, Hongbo Yang, Huijuan Zhu, Hui Pan, Fengying Gong","doi":"10.2174/0113892010375949250519062337","DOIUrl":"https://doi.org/10.2174/0113892010375949250519062337","url":null,"abstract":"<p><strong>Introduction: </strong>Hydroxysafflor Yellow A (HSYA), known for its anti-inflammatory effects in cardiovascular diseases, has also been shown to reduce adiposity and improve metabolic disorders in diet-induced obese (DIO) mice. However, the molecular mechanisms underlying its anti-obesity effects, particularly whether they are mediated through immune-inflammatory pathways, remain unclear. This study aims to identify the key molecular mechanisms involved in HSYA's anti-obesity action.</p><p><strong>Methods: </strong>Male C57BL/6J mice were divided into three groups: Standard Feed (SF), High-Fat Diet (HFD), and HFD with HSYA treatment (250 mg/kg/day for 9 weeks). Whole transcriptome sequencing of White Adipose Tissue (WAT) identified Differentially Expressed Genes (DEGs), which were integrated with network pharmacology predictions to identify key molecular targets of HSYA. RT-qPCR in WAT, 3T3-L1 adipocytes, and RAW264.7 macrophages validated the core genes, and molecular docking assessed HSYA's binding affinity with these targets.</p><p><strong>Results: </strong>HSYA treatment significantly reduced body weight (35.27 ± 1.27g vs. 45.46 ± 1.68g, p < 0.05) and WAT mass (3.38±0.21g vs. 1.86±0.27g, p < 0.05) in DIO mice and ameliorated glucose and lipid metabolism abnormalities. Transcriptome analysis revealed 739 DEGs, with 21 overlapping genes identified between sequencing and network pharmacology analyses. Experimental validation highlighted Prkcd, Btk, and Vav1 as core genes within immune-inflammatory pathways, including chemokine and B cell receptor signaling, which are implicated in obesityrelated inflammation. RT-qPCR confirmed the downregulation of Prkcd, Btk, and Vav1 after HSYA treatment, consistent with transcriptomic findings. Molecular docking analysis demonstrated strong binding affinities between HSYA and VAV1 (-8.5 kcal/mol), BTK (-6.9 kcal/mol), and PRKCD (-6.6 kcal/mol).</p><p><strong>Conclusion: </strong>HSYA demonstrates the therapeutic potential for obesity by modulating immuneinflammatory pathways in WAT, specifically targeting Prkcd, Btk, and Vav1 in mice. Given its clinical use in cardiovascular disease, these findings suggest that HSYA may offer broader therapeutic benefits, including obesity management, though further studies are needed to clarify the mechanisms and assess its applicability to humans.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}